🔗 Share this article

While the United States continues making historic adjustments to its vaccine schedules, a particular individual appears unexpectedly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by questioning Covid vaccinations in the pandemic and has concentrated on alleged deaths after Covid immunization in her recent tenure at the FDA.

Scheduled Overhauls to Pediatric Vaccine Program

Agency leaders had intended to unveil radical changes to the childhood immunization program recently, synchronizing the US with Denmark’s national calendar, sources say – a significant shift that would put the US at odds with a large portion of the international standard with insufficient data for public health gain. The announcement has been delayed until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to present at the event. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this calendar year.

A New Direction at the Regulatory Body

Høeg's temporary position might represent a tighter collaboration between the drug and biologics branches as Høeg and Prasad consolidate power at the agency – and it points to a renewed priority upon reevaluating already-approved vaccines at the FDA.

The new acting director has often pushed for halting specific pediatric shot schedules in the US in order to be more in line with the Danish model, a society with universal health coverage and a citizenry approximately the population of the state of Wisconsin.

To date comments, she has persisted in emphasizing on vaccination policy – traditionally the responsibility of Dr. Prasad, head of the FDA’s vaccine center – rather than drug regulation.

Doubts Over Qualifications

The appointee has no apparent experience in medication creation, regulation or administrative roles, which has been customary for past directors of the CBER. She has served at the FDA as a top consultant to the agency head and CBER since earlier this year.

“She appears not to have the requisite experience” for running the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in managing a large organization. She is not an expert in pharmaceutical oversight.”

Past directors of CBER would “understand legal statutes and the research of medication creation”, noted a former acting FDA commissioner. “Clearly, she doesn’t have the sort of resume that previous people who led CBER have had.”

This division has an enormous portfolio at the FDA, the former commissioner emphasized.

“The public just zeroes in on the novel medication approvals, but the generic drug division clears a multitude of generic drugs. There is also a biosimilars division, over-the-counter program and more, and all of those need to be supervised,” she said. “The responsibility you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a significant administrative aspect to the job, which manages more than 5,000 staff members. “It’s a enormous administrative position, if you perform it correctly,” Woodcock concluded.

Agency Reaction and Disputed Programs

When asked about questions about Dr. Høeg's credentials and whether this selection indicates more teamwork among FDA leaders on immunizations, a representative stated that the “inquiries are based on inaccurate presumptions”.

“Her experience aligns with the responsibilities of her position,” the official explained, noting the period Dr. Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a contentious expedited therapy clearance system that apparently worried her former heads. “By what process are these therapies being selected for this fast-track system? Who takes the calls?” Dr. Howard asked. “There’s a lot of confidentiality going on at the FDA right now.”

In general, he stated, “the FDA seems to be moving towards laxer oversight of all drugs, with the exception of immunizations.”

Documented Past Work on Vaccines

Concerning immunizations, Dr. Høeg has a more documented, if concerning, past, Howard have noted. She authored a study using unconfirmed crowd-sourced reports to determine the rate of heart inflammation after Covid immunization. She counseled the Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to imply Covid vaccinations are more dangerous than they are.

Part of her “policy goals” for the current administration encompassed revising guidelines for recently developed shots and halting “optional” immunizations, she stated following the vote on a podcast. At the agency, Høeg has according to sources floated the idea of preventing teenage boys from getting Covid vaccines.

“She’s an complete dogmatist who starts off with her beliefs and tailors the evidence to retrofit the data in a highly misleading, fraudulent way,” Howard said.

Consolidating Power and a “Revenge Tour”

Høeg joined fellow skeptics, {like|